RS26704A - Use of specific dose of fondaparinux sodium for the treatment of acs - Google Patents

Use of specific dose of fondaparinux sodium for the treatment of acs

Info

Publication number
RS26704A
RS26704A YUP-267/04A YUP26704A RS26704A RS 26704 A RS26704 A RS 26704A YU P26704 A YUP26704 A YU P26704A RS 26704 A RS26704 A RS 26704A
Authority
RS
Serbia
Prior art keywords
acs
treatment
sulfo
specific dose
sulfoamino
Prior art date
Application number
YUP-267/04A
Other languages
English (en)
Inventor
Anthonie Wilh.Arnold Lensing
Original Assignee
Sanofi-Synthelabo,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS26704(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Synthelabo, filed Critical Sanofi-Synthelabo,
Publication of RS26704A publication Critical patent/RS26704A/sr
Publication of RS50906B publication Critical patent/RS50906B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Pronalazak se odnosi na primenu doze od 2.5 mg pentasaharid metil O-(2-dezoksi-2-sulfoamino-6-O-sulfo-α-D-glukopiranozil)-(1→4)-O-(β-D-gluokpiranoziluronska kiselina)- (1→4) -O-(2-dezoksi-2-sulfoamido-3,6-di-O-sulfo-α-D-glukopiranozil)- (1→4)--O-(2-O-sulfo-α-L-idopiranozil uronska kiselina)- (1→4)--2-dezoksi-2-sulfoamino-6-O-sulfo-α-D-glukopiranozida ili njegove farmaceutski prihvatljive soli za dobijanje leka za lečenje akutnih koronarnih sindroma (ACS).
YUP-267/04A 2001-11-13 2002-11-07 Primena specifične doze natrijum fondaparinuksa za lečenje acs RS50906B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (2)

Publication Number Publication Date
RS26704A true RS26704A (en) 2007-02-05
RS50906B RS50906B (sr) 2010-08-31

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-267/04A RS50906B (sr) 2001-11-13 2002-11-07 Primena specifične doze natrijum fondaparinuksa za lečenje acs

Country Status (37)

Country Link
US (1) US20040248848A1 (sr)
EP (1) EP1446131B1 (sr)
JP (1) JP4523276B2 (sr)
KR (1) KR20050044318A (sr)
CN (1) CN1602197A (sr)
AP (1) AP1820A (sr)
AR (1) AR037291A1 (sr)
AT (1) ATE361753T1 (sr)
AU (1) AU2002351915B2 (sr)
BR (1) BR0212915A (sr)
CA (1) CA2465776A1 (sr)
CO (1) CO5580790A2 (sr)
CY (1) CY1106765T1 (sr)
DE (1) DE60220084T2 (sr)
DK (1) DK1446131T3 (sr)
EA (1) EA007325B1 (sr)
EC (1) ECSP045041A (sr)
ES (1) ES2287343T3 (sr)
GE (1) GEP20074097B (sr)
HK (1) HK1070561A1 (sr)
HR (1) HRP20040303B1 (sr)
HU (1) HU228959B1 (sr)
IL (2) IL161114A0 (sr)
IS (1) IS2484B (sr)
MA (1) MA27071A1 (sr)
ME (2) ME00229B (sr)
MX (1) MXPA04003045A (sr)
NO (1) NO20041320L (sr)
NZ (1) NZ552129A (sr)
PE (1) PE20030740A1 (sr)
PL (1) PL206008B1 (sr)
PT (1) PT1446131E (sr)
RS (1) RS50906B (sr)
SI (1) SI1446131T1 (sr)
UA (1) UA80399C2 (sr)
WO (1) WO2003041722A1 (sr)
ZA (1) ZA200402464B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US20040087543A1 (en) * 2002-04-25 2004-05-06 Zachary Shriver Methods and products for mucosal delivery

Also Published As

Publication number Publication date
NO20041320L (no) 2004-06-14
JP4523276B2 (ja) 2010-08-11
EA200400382A1 (ru) 2004-10-28
KR20050044318A (ko) 2005-05-12
HUP0401462A2 (en) 2006-02-28
DK1446131T3 (da) 2007-09-10
JP2005509007A (ja) 2005-04-07
AR037291A1 (es) 2004-11-03
MEP1108A (en) 2011-02-10
DE60220084D1 (de) 2007-06-21
CY1106765T1 (el) 2012-05-23
AP2004003014A0 (en) 2004-06-30
HUP0401462A3 (en) 2006-04-28
RS50906B (sr) 2010-08-31
IS2484B (is) 2008-12-15
IS7199A (is) 2004-03-29
ES2287343T3 (es) 2007-12-16
CO5580790A2 (es) 2005-11-30
MXPA04003045A (es) 2005-06-20
PT1446131E (pt) 2007-08-07
ZA200402464B (en) 2005-06-29
ATE361753T1 (de) 2007-06-15
BR0212915A (pt) 2004-10-13
GEP20074097B (en) 2007-05-10
PL369027A1 (en) 2005-04-18
NZ552129A (en) 2008-04-30
ME00229B (me) 2011-10-10
HK1070561A1 (en) 2005-06-24
EP1446131A1 (en) 2004-08-18
ECSP045041A (es) 2004-04-28
HU228959B1 (en) 2013-07-29
IL161114A (en) 2010-11-30
IL161114A0 (en) 2004-08-31
HRP20040303A2 (en) 2004-10-31
AP1820A (en) 2008-01-11
EA007325B1 (ru) 2006-08-25
DE60220084T2 (de) 2008-01-10
MA27071A1 (fr) 2004-12-20
EP1446131B1 (en) 2007-05-09
WO2003041722A1 (en) 2003-05-22
PL206008B1 (pl) 2010-06-30
HRP20040303B1 (en) 2012-02-29
CA2465776A1 (en) 2003-05-22
US20040248848A1 (en) 2004-12-09
SI1446131T1 (sl) 2007-10-31
AU2002351915B2 (en) 2007-11-29
UA80399C2 (en) 2007-09-25
CN1602197A (zh) 2005-03-30
PE20030740A1 (es) 2003-08-28

Similar Documents

Publication Publication Date Title
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
WO1999044581A3 (en) Pharmaceutical composition of topiramate
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
EP1537859A3 (en) Azithromycin dosage forms with reduced side effects
IL114641A0 (en) Pharmaceutical compositions containing fluoxetine
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
IL151628A0 (en) Combination therapies with vascular damaging activity
NO994431L (no) Ny formulering
IL136196A0 (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HUP0203471A3 (en) Antithrombotic compound, process for their preparation, pharmaceutical compositions containing them and their use
CY1106765T1 (el) Χρηση ειδικης δοσης του νατριουχου φονταπαρινιδιου για τη θεραπεια των acs
ES2176009T3 (es) Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.
EP1162884A4 (en) LOW-DOSE ORAL COMPOSITIONS OF BUTYRATE COMPOSITIONS
GEP20043377B (en) Pharmaceutical Complex
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
JP2005509007A5 (sr)
CA2472957A1 (en) Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
JP2005519919A5 (sr)
EA199800848A1 (ru) Гиполипидемическое и антиатеросклеротическое средство
HU9800835D0 (en) Pharmaceutical composition for treatment diseases causing by ascophaera apis
UA34350A (uk) Спосіб комплексного лікування генералізованого пародонтиту